AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

Claims 1 and 2 (Canceled).

Claim 3 (Currently amended). A method for treating [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula III





III

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.

Claims 4 and 5 (Cancelled).

Claim 6 (Currently amended). A method for treating [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula VI



VI

or a pharmaceutically acceptable salt thereof,

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or

R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; and

n is an integer from 0 to 6.

Claim 7 (Currently amended). A compound selected from the group consisting of:

Isophthalic acid di-(2,1,3-benzothiadiazol-5-yl) methyl ester;

4-Methoxy-isophthalic acid dipyridin-4-ylmethyl ester;

N,N'-Bis-1,3-benzodioxol-5-ylmethyl-4-methoxy-isophthalamide;

N-1,3-Benzodioxol-5-ylmethyl-N'-furan-2-ylmethyl-isophthalamide;

4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester;

N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;

[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;]

N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;

N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;

4-Amino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;

4-Acetylamino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;

N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;

[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;]

N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-propoxy-isophthalamide; and

[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;]

N1,N3-Bis-2,1,3-benzothiadiazol-5-ylmethyl-4-methoxy-isophthalamide[;

and

4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester].

Claims 8 to 17 (Cancelled).

Claim 18 (Currently amended). A compound of Formula III





III

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.

Claim 19 (Previously presented). A pharmaceutical composition, comprising a compound of Claim 18, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 20 (Canceled).

Claim 21 (Previously presented). A method for treating rheumatoid arthritis, the method comprising administering to a patient suffering from rheumatoid arthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 22 (Previously presented). A method for treating osteoarthritis, the method comprising administering to a patient suffering from osteoarthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 23 (Previously presented). A method for treating heart failure, the method comprising administering to a patient suffering from heart failure a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.